Harrow, Inc. Common Stock (HROW) is a publicly traded Healthcare sector company. As of May 21, 2026, HROW trades at $30.58 with a market cap of $1.15B and a P/E ratio of -79.81. HROW moved +0.88% today. Year to date, HROW is -43.69%; over the trailing twelve months it is +9.94%. Its 52-week range spans $20.85 to $59.23. Analyst consensus is strong buy with an average price target of $67.17. Rallies surfaces HROW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Harrow Q1 Revenue Hit by VEVYE Coverage Gap and High-Deductible Patients: Harrow's Q1 revenue fell short due to a discrete coverage gap with VEVYE and a rise in high-deductible patient receivables, pressuring total reported sales. Management highlighted accelerating underlying demand for its core ophthalmic products, citing sequential order growth for its retina and glaucoma treatment portfolio.
| Metric | Value |
|---|---|
| Price | $30.58 |
| Market Cap | $1.15B |
| P/E Ratio | -79.81 |
| EPS | $-0.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.23 |
| 52-Week Low | $20.85 |
| Volume | 81 |
| Avg Volume | 0 |
| Revenue (TTM) | $268.68M |
| Net Income | $-14.96M |
| Gross Margin | 74.11% |
8 analysts cover HROW: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $67.17.